---
granola_id: b488e57a-f507-4d65-97b3-2a8d8da51dd9
title: "mina call emre"
type: note
created: 2025-05-02T13:28:44.850Z
updated: 2025-05-02T14:04:20.823Z
attendees:
  - mina.iskarous@gmail.com
  - sd@virtuevc.com
---
### Background - Mina

- Prior experience at Ribbon Health (6-7 person team)
- Well Dot (Boston/Chapel Hill) - 2 years product work
	- $25M GC seed round, 40 person team
	- Care navigation and behavior change for employers
- HouseRx - First product hire, joined at 5-6 people
	- Now at 70 pharmacies, $20M in revenue
	- Built core product through Series B
	- Launched Gen AI prior auth suite
		- Reduced processing time from 6-7 mins (questions) + 10-12 mins (back/forth) to ~1 min
		- Potential for autonomous submissions with high confidence

### Cell & Gene Therapy Opportunity

- Market Size & Growth
	- Current: $600M in drug spend
	- 5-year projection: $30B
	- 10-year projection: Up to $120B
- Access & Infrastructure
	- 35 states enrolled for gene therapy sickle cell (Medicaid 75% reimbursement)
	- Limited sites: <30 centers of excellence/qualified treatment centers per therapeutic
- Target Areas
	- Gene therapy for sickle cell
	- Cell therapy in oncology
	- Cell therapy for autoimmune conditions
	- Radiopharmaceuticals/radioligands (e.g. prostate cancer)

### Business Model Components

- Technology Platform
	- Patient identification/referrals
	- Administrative/operational support
	- Payment processing
	- Post-treatment data collection
- Revenue Strategy
	- Drug margin participation (learning from HouseRx)
	- AI-enabled hub services for pharma
- Expansion Plan
	- Start with academic medical centers
	- Expand to hospitals/health systems
	- Long-term: Enable community practice delivery

### Go-to-Market Approach

- 4-month initial validation phase through September
- Target stakeholder conversations:
	- Academic medical centers (CHOP, Dana Farber, UPenn)
	- Medicaid programs
	- Hospitals/health systems
	- Pharma companies (e.g. Bluebird, Vertex)
- Focus on operations/care delivery expertise
- Leverage lessons from existing JVs (e.g. Shields 340B with MGH)

### Team & Structure

- Core initial team:
	- Commercial/COO cofounder (from Little Otter)
	- Head of Engineering
	- Operations lead with medical benefit experience
- Advisory needs:
	- Scientific advisors
	- Pharma expertise
	- Hospital/AMC operations
- Plan to build lean, AI-native organization in NYC
- Timeline: Full launch planned for December post-validation

Chat with meeting transcript: https://notes.granola.ai/d/b488e57a-f507-4d65-97b3-2a8d8da51dd9
